AI summary by TwinMind

China's Vaccine Diplomacy

Wendover Productions

17m 47s

China's Early Pandemic Response and Image Recovery Efforts

  • Spring 2020: China emerged triumphant from COVID lockdown while rest of world entering pandemic
  • Focused on recovering from global image hit due to perceived early virus mismanagement
  • Attempted to be viewed as country that crushed COVID domestically and led global fight
  • Supplied ventilators to JFK airport, medical supplies via national airlines, test kits globally
  • Positioned itself at center of global virus fight

Quality Issues with Chinese Medical Supplies

  • Donations turned to purchases, revealing major quality problems
  • 90% of mask certifications from China were fake according to one measure
  • Tests supposed to have 80% sensitivity actually had 30%
  • Chinese officials demanded public displays of thanks for donations
  • Reinforced "Chinese-made as inferior" narrative
  • Diplomacy effort potentially further damaged global image

Chinese Vaccine Development Timeline

  • Multiple private companies, state-owned enterprises, government institutes began vaccine work
  • Spring 2020: Strong viable candidates emerged
  • March 17, 2020: First Chinese vaccine (Ad5-nCoV by CanSino Biologics) entered Phase 1 trial
    • 108 adults in Wuhan received shots
  • April 11: Became first vaccine worldwide to enter Phase 2 trials (508 participants)
  • July 20: Results showed vaccine was safe and generated desired immune response

Phase 3 Trial Challenges

  • Phase 3 trials test real-world effectiveness by comparing vaccine vs. placebo groups
  • Problem: China's daily COVID cases reduced to double-digit levels by late summer
  • In country of 1+ billion, most Phase 3 trials have <50,000 participants
  • Would take years/decades at those caseloads to get hundreds of infections needed
  • Impossible to complete COVID vaccines in China due to successful virus suppression

International Phase 3 Trials and Diplomatic Arrangements

  • CanSino Ad5-nCoV vaccine started Phase 3 trials in Russia, Pakistan, Saudi Arabia, Mexico, Argentina, Chile
  • Other candidates moved to dozens of countries with severe COVID epidemics
  • China had to curry favor with each government
  • Typically offered priority access to vaccines being tested in exchange for trial hosting

Chinese Vaccine Approval and Deployment

  • Five Chinese-made vaccines approved in country
  • Widespread criticism of development practices:
    • Started vaccinating public before Phase 3 trials reached endpoints
    • Not forthcoming with clinical trial data
    • Misrepresented efficacy ratings
  • December 30: BBIBP-CorV vaccine by Sinopharm approved, one of first COVID vaccines deployed globally
  • Despite evidence vaccines are acceptably safe/effective, potentially less so than other approved vaccines

Global Vaccine Distribution Strategy

  • Despite 1.4 billion people to inoculate, first doses sent beyond borders
  • Sinopharm has orders from 100+ countries (details not publicly known)
  • Goal: succeed where masks/ventilators/tests failed in 2020
  • Western vaccines (Moderna/Pfizer): 95% efficacy vs. Chinese vaccines: 50-83%
  • Western vaccines have order obligations into 2022, Chinese vaccines more available
  • Countries choosing less effective vaccine sooner vs. waiting for better alternatives

Vaccine Diplomacy and Free Distribution

  • Major diplomacy coup: historically Western-allied countries (Hungary, Mexico) turning to China
  • Free vaccine distributions:
    • Mongolia, Sri Lanka: 300,000 doses
    • Algeria, Sierra Leone, Zimbabwe: 200,000 doses
    • Belarus, Equatorial Guinea, Gabon, Mozambique, Namibia, Bolivia: 100,000 doses
  • Amounts sufficient for healthcare worker vaccination news clips
  • Demonstrates safety/effectiveness, encouraging larger orders

Diplomatic Influence and Taiwan Relations

  • State-owned enterprise distribution raises questions about diplomatic-based allocation
  • Algeria example: Chinese official noted 50-year-old UN vote switching recognition from Taiwan to PRC
  • Mentioned Algeria's Belt and Road Initiative participation before announcing 200,000 vaccine donation
  • South America: 10 of 12 countries vaccinated with Chinese vaccines
  • Only exceptions: Suriname (lowest population) and Paraguay
  • Paraguay recognizes Taiwan as independent nation
  • Zero overlap between countries recognizing Taiwan and those receiving Chinese vaccines

Brazil-Huawei-Vaccine Connection

  • Brazil-US relations strong under Bolsonaro/Trump
  • Brazil banned Huawei from 5G network following US lead
  • February: Brazilian communications minister Fabio Faria visited Beijing, met Huawei executives
  • Faria "took advantage of trip to ask for vaccines"
  • Chinese ambassador letter emphasized cooperation importance
  • Weeks later: Brazil changed 5G auction rules to allow Huawei participation
  • Huawei didn't deny tit-for-tat deal, said they could "facilitate communication" between governments

Manufacturing Challenges and Domestic Vaccination Lag

  • mRNA vaccines (Moderna/Pfizer) relatively easy to manufacture
  • Chinese vaccines use attenuated/dead virus or portions - time-consuming, harder to scale
  • mRNA vaccines include genetic instructions for spike protein creation
  • Chinese vaccine production slower due to:
    • Slow manufacturing process
    • Priority obligations to trial hosting countries
    • Robust vaccine diplomacy program
    • Insistence on Chinese-made vaccines only

Domestic Vaccination Statistics (as of March)

  • China: 5 doses per 100 citizens
  • EU countries: 10-15 per 100
  • US: 35 per 100
  • UK: 42 per 100
  • Estimates: China will achieve widespread vaccination end of 2022
  • Same timeframe as India, Iran, Egypt, Ethiopia, Colombia
  • Western world expected back to normal at least a year earlier

Strategic Implications and Image Concerns

  • China's goal: be viewed as equal to US/Europe superpower status
  • Risk of prolonged border restrictions, lockdowns, economic uncertainty
  • Domestic and international questions about prioritizing foreign distribution
  • Questions about not purchasing more effective foreign vaccines
  • Potential narrative control loss affecting foreign and domestic image
  • Risk of suffering in COVID-19's "third and final act"

TwinMind

Get summaries like this for your own meetings

TwinMind takes notes in the background during meetings, lectures, and calls, then writes the summary for you.

Free plan to get started

No bot joins your calls

Phone, desktop & Chrome apps

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome